Mimedx Group Inc SEC Filings

MiMedx Group (MDXG) furnished its quarterly results update. The company announced it issued a press release with financial results for the quarter ended September 30, 2025, and furnished it under Item 2.02. The materials include an Earnings Press Release (Exhibit 99.1), an Earnings Call presentation (Exhibit 99.2), and an Investor Presentation (Exhibit 99.3).

Management scheduled a conference call and webcast on October 29, 2025, at 4:30 PM Eastern Daylight Time to discuss the quarter. The information in Items 2.02 and 7.01 is furnished, not filed, under the Exchange Act.

MiMedx Group (MDXG) reported a strong Q3 2025. Net sales rose to $113.7 million, up 35% year over year, driven by newer Wound products CELERA and EMERGE and broad-based Surgical strength. Wound sales reached $77.1 million (up 40%), and Surgical sales were $36.6 million (up 26%). Gross margin improved to 83.5% from 81.8% on favorable production variances and mix.

GAAP net income was $16.7 million with diluted EPS of $0.11, versus $0.05 a year ago, as operating income doubled to $22.2 million. Cash and equivalents increased to $142.1 million, supported by $49.0 million in operating cash flow year to date. The company ended the quarter with $18.3 million of term debt at a 6.5% rate and no borrowings on its revolver. Management highlighted potential reimbursement changes starting January 1, 2026, with CMS proposing a fixed price of $125.38 per square centimeter for skin substitutes across settings; final rules are expected this year.

MiMedx Group, Inc. (MDXG) disclosed that it will participate in the Cantor Global Healthcare Conference on September 3, 2025 and has updated its investor presentation. The presentation materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated by reference. The filing reiterates standard forward-looking statement language, noting that actual results may differ due to risks such as uncertain future sales, reimbursement dynamics, scientific outcomes, international commercialization challenges, and regulatory developments. The disclosure clarifies that the furnished information is not deemed "filed" for certain Exchange Act liabilities and is not automatically incorporated into other securities filings.

MiMedx Group Chief Commercial Officer Kimberly Maersk-Moller reported a Form 4 filing on June 28, 2025, disclosing a transaction dated June 24, 2025. The insider disposed of 12,034 shares of Common Stock at a price of $5.96 per share through a tax withholding transaction (Code F).

Key Transaction Details:

• The shares were withheld for payment of tax liability upon vesting of restricted stock units
• Following the transaction, Maersk-Moller directly owns 295,282 shares of Common Stock
• The transaction was executed under a Form 4 filing obligation pursuant to Section 16(a) of the Securities Exchange Act

This routine tax-related share withholding suggests the vesting of previously awarded restricted stock units, rather than an open market sale decision by the insider.

MiMedx Group Director Todd Newton received an annual restricted stock grant of 28,609 shares at $6.47 per share on June 18, 2025, increasing his direct beneficial ownership to 412,771 shares.

Key details of the transaction:

• The grant is exempt under Rule 16b-3 as part of non-employee director compensation
• Vesting occurs at the earlier of 12 months or next annual shareholder meeting
• Transaction was filed via Form 4 on June 28, 2025
• Filing was signed by William F. Hulse as attorney-in-fact

This routine compensation grant reflects standard board member equity incentives and demonstrates continued alignment between director and shareholder interests.